OMER Omeros Corporation Stock Quote

OMER [NASD]

Index	-	P/E	-	EPS (ttm)	-3.13	Insider Own	4.03%	Shs Outstand	62.73M	Perf Week	35.16%
Market Cap	188.14M	Forward P/E	-	EPS next Y	-1.79	Insider Trans	0.00%	Shs Float	60.20M	Perf Month	22.31%
Income	-196.00M	PEG	-	EPS next Q	-0.64	Inst Own	46.50%	Short Float	21.74%	Perf Quarter	-50.83%
Sales	-	P/S	-	EPS this Y	-1.50%	Inst Trans	-5.78%	Short Ratio	11.81	Perf Half Y	-59.34%
Book/sh	-0.08	P/B	-	EPS next Y	5.20%	ROA	-	Target Price	12.00	Perf Year	-80.75%
Cash/sh	2.24	P/C	1.32	EPS next 5Y	-	ROE	-	52W Range	1.86 - 16.57	Perf YTD	-53.97%
Dividend	-	P/FCF	-	EPS past 5Y	-13.20%	ROI	-	52W High	-82.14%	Beta	0.75
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	59.57%	ATR	0.32
Employees	213	Current Ratio	6.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	55.75	Volatility	22.01% 13.02%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-11.10%	Profit Margin	-	Rel Volume	1.27	Prev Close	3.18
Shortable	Yes	LT Debt/Eq	-	Earnings	May 10 AMC	Payout	-	Avg Volume	1.11M	Price	2.96
Recom	2.20	SMA20	25.97%	SMA50	-0.93%	SMA200	-53.81%	Volume	1,386,382	Change	-6.92%

Jun-08-22

Downgrade

BofA Securities

Buy → Neutral

$12 → $4

Oct-08-21

Downgrade

JP Morgan

Neutral → Underweight

Oct-01-21

Downgrade

Wedbush

Neutral → Underperform

Oct-01-21

Downgrade

Maxim Group

Buy → Hold

Sep-27-21

Initiated

JP Morgan

Neutral

$15

Feb-01-21

Initiated

UBS

Buy

$25

Oct-20-20

Initiated

BofA Securities

Buy

$21

Aug-21-20

Reiterated

H.C. Wainwright

Buy

$34 → $32

Aug-14-20

Reiterated

Maxim Group

Buy

$25 → $20

May-06-19

Initiated

Cantor Fitzgerald

Overweight

$26

Jul-12-18

Initiated

Seaport Global Securities

Buy

$30

Mar-23-18

Downgrade

Wedbush

Outperform → Neutral

$47 → $19

Mar-05-18

Downgrade

Needham

Buy → Hold

Nov-08-17

Initiated

H.C. Wainwright

Buy

$30

May-11-17

Downgrade

Cantor Fitzgerald

Buy → Neutral

$21 → $15

Mar-17-17

Reiterated

Needham

Buy

$24 → $22

Mar-17-17

Reiterated

Maxim Group

Buy

$19 → $22

Nov-16-16

Reiterated

Wedbush

Outperform

$56 → $47

Nov-10-16

Reiterated

Needham

Buy

$28 → $24

Aug-10-16

Reiterated

Maxim Group

Buy

$30 → $19

Jun-15-22 08:00AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders Business Wire +5.13%
May-10-22 04:02PM	Omeros Corporation Reports First Quarter 2022 Financial Results Business Wire
May-04-22 08:30AM	Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022 Business Wire +6.06%
Apr-20-22 08:45AM	Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA Business Wire -8.30%
Mar-01-22 04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results Business Wire
08:59AM	How Much Of Omeros Corporation (NASDAQ:OMER) Do Institutions Own? Simply Wall St.
Feb-28-22 08:34AM	Why Earnings Season Could Be Great for Omeros (OMER) Zacks
Feb-24-22 07:00AM	Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022 Business Wire +7.74%
Feb-03-22 09:38AM	Bellevue Asset Management, Llc Buys First Trust Low Duration Mortgage Opportunities ET, eBay ... GuruFocus.com
Jan-20-22 06:54AM	Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA Benzinga
Jan-19-22 05:52PM	Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA Business Wire
Dec-30-21 05:11PM	Omeros receives $126M in sale of drug franchise to British eye care company American City Business Journals
Dec-23-21 09:10AM	Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical Business Wire
Dec-20-21 09:30AM	OMER EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation - OMER PR Newswire +5.59%
Dec-15-21 11:34AM	Do Options Traders Know Something About Omeros (OMER) Stock We Don't? Zacks
Dec-03-21 08:17PM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm Newsfile -6.15%
Dec-02-21 08:22PM	Seattle biotech Omeros selling drug franchise in deal valued at over $1B American City Business Journals +7.33%
07:30AM	Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion Business Wire
05:58AM	Omeros Shares Rally On Agreement to Sell Omidria Cataract Business Investing.com
Nov-30-21 07:42AM	Investors in Omeros (NASDAQ:OMER) have unfortunately lost 50% over the last three years Simply Wall St.
Nov-09-21 06:25PM	Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:02PM	Omeros Corporation Reports Third Quarter 2021 Financial Results Business Wire
Nov-05-21 04:45PM	Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years Benzinga
08:40AM	Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial Business Wire
08:30AM	Omeros Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis Business Wire
Nov-04-21 10:53AM	Wall Street Analysts See a 192% Upside in Omeros (OMER): Can the Stock Really Move This High? Zacks
08:30AM	Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021 Business Wire
Nov-01-21 04:35PM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +9.73%
03:01PM	Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-31-21 06:19AM	3 Beaten-Down Biotech Stocks -- Can They Recover? Motley Fool
Oct-26-21 03:15PM	INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-21-21 10:00AM	Down 59.6% in 4 Weeks, Here's Why Omeros (OMER) Looks Ripe for a Turnaround Zacks
Oct-20-21 08:31AM	Omeros (OMER) Soars 9.7%: Is Further Upside Left in the Stock? Zacks
Oct-18-21 05:39PM	Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA Benzinga -26.65%
12:24PM	Here's Why Omeros Is Sinking Further Today Motley Fool
06:30AM	Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA Business Wire
Oct-15-21 09:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PR Newswire
Oct-13-21 06:40PM	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
04:35PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER ACCESSWIRE
Oct-11-21 03:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER GlobeNewswire +6.87%
Oct-07-21 10:30PM	OMEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Omeros Corporation on Behalf of Omeros Stockholders and Encourages Investors to Contact the Firm Business Wire
09:45PM	OMER EQUITY ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation - OMER PR Newswire
12:16PM	INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm PR Newswire
Oct-06-21 04:00PM	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors Business Wire
Oct-05-21 06:32PM	Omeros: Uncertainty Ahead Merits a Downgrade TipRanks
04:51PM	INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors Business Wire
10:10AM	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm Business Wire
Oct-04-21 03:11PM	INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Omeros Corporation and Encourages Investors With Losses to Contact the Firm Business Wire -14.75%
01:11PM	OMER INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation OMER Business Wire
Oct-03-21 08:51PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
Oct-01-21 05:02PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER Newsfile -38.07%
04:05PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Omeros Corporation (OMER) Investigation ACCESSWIRE
12:47PM	Mid-Day Market Update: Dow Surges 300 Points; Omeros Shares Plummet Benzinga
12:41PM	35 Stocks Moving In Friday's Mid-Day Session Benzinga
12:11PM	Here's Why Omeros Stock Is Tanking Today Motley Fool
08:55AM	Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA Business Wire
08:32AM	Do Options Traders Know Something About Omeros (OMER) Stock We Don't? Zacks
Sep-30-21 08:36PM	Why Omeros Stock Is Plummeting This Week Motley Fool
Aug-09-21 05:35PM	Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:02PM	Omeros Corporation Reports Second Quarter 2021 Financial Results Business Wire
Aug-03-21 08:30AM	Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021 Business Wire
Aug-02-21 03:01PM	Earnings Preview: Omeros (OMER) Q2 Earnings Expected to Decline Zacks
08:24AM	Here's What Omeros Corporation's (NASDAQ:OMER) Shareholder Ownership Structure Looks Like Simply Wall St.
Jun-14-21 12:45PM	Omeros' Narsoplimab Associated With Improvement In Organ Function In Stem Cell Transplant Patients Benzinga
08:30AM	Omeros Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association Business Wire
Jun-10-21 03:53PM	Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor Zacks
08:45AM	Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction Business Wire
Jun-09-21 05:00PM	Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference Business Wire
08:45AM	Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906 Business Wire
Jun-07-21 10:39PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
12:39PM	Novartis (NVS) Posts Positive Data on Kidney Disease Candidate Zacks
Jun-05-21 08:01PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER Newsfile
Jun-02-21 10:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
Jun-01-21 05:05AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PR Newswire
May-31-21 05:16PM	Omeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients Zacks
May-29-21 10:29PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER Newsfile
May-28-21 12:00PM	Omeros's Narsoplimab Shows Encouraging Action In Critically Ill COVID-19 Patients Benzinga
08:45AM	Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab Business Wire
May-27-21 10:08PM	Omeros Corporation Investors: Company Investigated by the Portnoy Law Firm GlobeNewswire
02:37PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
May-26-21 09:13AM	Biotech Stock Roundup: MRNA's Vaccine Update & Pipeline Updates From REGN, BMY Zacks
May-22-21 10:48PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER Newsfile
May-21-21 09:55AM	Omeros' (OMER) BLA for Narsoplimab Gets Extended Review Zacks
May-20-21 02:40PM	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Omeros Corporation (OMER) and Encourages Investors to Contact the Firm ACCESSWIRE -10.78%
08:45AM	Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA Business Wire
May-13-21 08:30AM	Omeros Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress Business Wire
May-10-21 05:55PM	Omeros (OMER) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:02PM	Omeros Corporation Reports First Quarter 2021 Financial Results Business Wire
02:30PM	Omeros Corp. to Host Earnings Call ACCESSWIRE
May-05-21 08:45AM	Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021 Business Wire
May-04-21 05:45AM	Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration Business Wire
05:15AM	Omeros (NASDAQ:OMER) Shareholders Have Enjoyed A 42% Share Price Gain Simply Wall St.
Mar-23-21 08:45AM	Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial Business Wire
Mar-01-21 05:25PM	Omeros (OMER) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:18PM	Recap: Omeros Q4 Earnings Benzinga
04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results Business Wire
02:30PM	Omeros Corp. to Host Earnings Call ACCESSWIRE
Feb-25-21 09:37AM	Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021 Business Wire -14.45%
Feb-03-21 05:30AM	How Many Omeros Corporation (NASDAQ:OMER) Shares Do Institutions Own? Simply Wall St.
Jan-26-21 08:45AM	Omeros Hires Nadia Dac as Chief Commercial Officer Business Wire

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HANISH ARNOLD C	Director	Sep 08	Option Exercise	9.44	10,000	94,400	10,000	Sep 09 05:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience